Adalimumab

Adalimumab Reactions 1680, p16 - 2 Dec 2017 Subacute thyroiditis and thyrotoxicosis: case report A 50-year-old woman developed subacute thyroiditis (SAT) and thyrotoxicosis during treatment with adalimumab. The woman, who was diagnosed with psoriatic arthritis in 2013, was on SC adalimumab 40mg every other week. She was admitted due to complaints of fever from two weeks and pharyngeal pain. She received treatment with amoxicillin without effect. Rapidly, a painful thyroid goiter with clinical signs of thyrotoxicosis appeared. Blood tests showed systemic inflammation with a c-reactive protein of 115 mg/L) and hyperthyroidism with undetectable circulating thyroid stimulating hormone and increased T4 and T3 levels. Anti- thyroid antibodies were negative, except for anti-thyroglobulin antibodies of 351 UI/mL. Ultrasonography of thyroid showed an increased hypervascularised pattern. Iodine 123 scintiggraphy revealed asymmetric fixation capture at the lower normal limit. She was diagnosed with SAT was made [duration of treatment to reaction onset not stated]. The woman was treated with aspirin [acetylsalicylic acid] with no efficacy. Then, she was treated with unspecified corticosteroids for two weeks and progressive decay was administered. Her symptoms improved significantly and progressive hypothyroidism appeared. Adalimumab was not restarted. Author comment: "We report here a subacute thyroiditis in a [psoriatic arthritis] patient treated by adalimumab. The physician might be aware of this unusual complication of [TNF inhibitor]." Senlis M, et al. Subacute thyroiditis in psoriatic arthritis treated by adalimumab. Joint Bone Spine 84: 745-746, No. 6, Dec 2017. Available from: URL: http:// doi.org/10.1016/j.jbspin.2016.09.015 - France 803285194 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Adalimumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/adalimumab-xHZvm0xGMW
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38947-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p16 - 2 Dec 2017 Subacute thyroiditis and thyrotoxicosis: case report A 50-year-old woman developed subacute thyroiditis (SAT) and thyrotoxicosis during treatment with adalimumab. The woman, who was diagnosed with psoriatic arthritis in 2013, was on SC adalimumab 40mg every other week. She was admitted due to complaints of fever from two weeks and pharyngeal pain. She received treatment with amoxicillin without effect. Rapidly, a painful thyroid goiter with clinical signs of thyrotoxicosis appeared. Blood tests showed systemic inflammation with a c-reactive protein of 115 mg/L) and hyperthyroidism with undetectable circulating thyroid stimulating hormone and increased T4 and T3 levels. Anti- thyroid antibodies were negative, except for anti-thyroglobulin antibodies of 351 UI/mL. Ultrasonography of thyroid showed an increased hypervascularised pattern. Iodine 123 scintiggraphy revealed asymmetric fixation capture at the lower normal limit. She was diagnosed with SAT was made [duration of treatment to reaction onset not stated]. The woman was treated with aspirin [acetylsalicylic acid] with no efficacy. Then, she was treated with unspecified corticosteroids for two weeks and progressive decay was administered. Her symptoms improved significantly and progressive hypothyroidism appeared. Adalimumab was not restarted. Author comment: "We report here a subacute thyroiditis in a [psoriatic arthritis] patient treated by adalimumab. The physician might be aware of this unusual complication of [TNF inhibitor]." Senlis M, et al. Subacute thyroiditis in psoriatic arthritis treated by adalimumab. Joint Bone Spine 84: 745-746, No. 6, Dec 2017. Available from: URL: http:// doi.org/10.1016/j.jbspin.2016.09.015 - France 803285194 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off